{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:30:57Z","timestamp":1789133457315,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009992","name":"Seattle Children's Research Institute","doi-asserted-by":"publisher","award":["BE-101"],"award-info":[{"award-number":["BE-101"]}],"id":[{"id":"10.13039\/100009992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ymthe.2025.09.001","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:19:49Z","timestamp":1757092789000},"page":"266-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7724-9103","authenticated-orcid":false,"given":"Hanlan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshisingh","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Shenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charuta","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamael","family":"Dastagir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Bainter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Liberzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor R.","family":"Malloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cicera R.","family":"Lazzarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro K.","family":"Ohsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Chilakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja F.","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Arlauckas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lazorchak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Scull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.09.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.09.001_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221085202","article-title":"International consensus recommendations on the management of people with haemophilia B","volume":"13","author":"Hart","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13397","article-title":"Individualized PK-based prophylaxis in severe haemophilia","volume":"24","author":"Dargaud","year":"2018","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.09.001_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The benefits of prophylaxis in patients with hemophilia B","volume":"11","author":"Castaman","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib7","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ymthe.2025.09.001_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MBC.0000000000000885","article-title":"Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B","volume":"31","author":"Chhabra","year":"2020","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.ymthe.2025.09.001_bib9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene Elaparvovec: First Approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.09.001_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.09.001_bib13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of Humoral Immunity to Common Viral and Vaccine Antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejim.2021.05.028","article-title":"kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers","volume":"89","author":"Varona","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/imr.12656","article-title":"Immunological memories of the bone marrow","volume":"283","author":"Chang","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2025.09.001_bib16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","article-title":"Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells","volume":"26","author":"Hung","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2024.12.042","article-title":"In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model","volume":"33","author":"Young","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib18","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3324\/haematol.2019.229047","article-title":"Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study","volume":"105","author":"Hao","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.09.001_bib19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/bioinformatics\/btz867","article-title":"CRISPRitz: rapid, high-throughput and variant-aware in silico off-target site identification for CRISPR genome editing","volume":"36","author":"Cancellieri","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.09.001_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nmeth.4284","article-title":"Mapping the genomic landscape of CRISPR\u2013Cas9 cleavage","volume":"14","author":"Cameron","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2025.09.001_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.it.2011.09.001","article-title":"Staying alive: regulation of plasma cell survival","volume":"32","author":"Tangye","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib24","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/eji.1830191121","article-title":"High- and low-affinity receptors for murine interleukin 6. distinct distribution on b and t cells","volume":"19","author":"Coulie","year":"1989","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13104-019-4137-z","article-title":"On the length, weight and GC content of the human genome","volume":"12","author":"Piovesan","year":"2019","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ymthe.2025.09.001_bib26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/dmd.121.000417","article-title":"Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration\u2013Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Migliorati","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ymthe.2025.09.001_bib27","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib28","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.09.001_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","article-title":"Autologous gene therapy for hemoglobinopathies: From bench to patient\u2019s bedside","volume":"32","author":"Locatelli","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene Autotemcel Gene Therapy for Non\u2013\u03b20\/\u03b20 Genotype \u03b2-Thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib33","doi-asserted-by":"crossref","first-page":"9848","DOI":"10.3390\/ijms25189848","article-title":"Recent Advancements in Cell-Based Therapies in Melanoma","volume":"25","author":"Nassief","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.09.001_bib34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","article-title":"Engineering the next generation of cell-based therapeutics","volume":"21","author":"Bashor","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.09.001_bib35","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/j.jtha.2024.07.012","article-title":"Adeno-associated viral vector integration: implications for long-term efficacy and safety","volume":"22","author":"Batty","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.09.001_bib36","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/mt.2016.52","article-title":"Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients","volume":"24","author":"Gil-Farina","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib37","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101111","article-title":"Production of therapeutic levels of human FIX-R338L by engineered B cells using GMP-compatible medium","volume":"31","author":"David","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.09.001_bib39","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1016\/j.ymthe.2024.06.004","article-title":"Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing","volume":"32","author":"Hill","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib40","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib41","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.09.001_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","article-title":"Enhanced Factor IX Activity following Administration of AAV5-R338L \u201cPadua\u201d Factor IX versus AAV5 WT Human Factor IX in NHPs","volume":"15","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.09.001_bib44","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.09.001_bib45","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types","volume":"26","author":"Monaco","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2025.09.001_bib46","first-page":"1341","article-title":"Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection","volume":"151","author":"Rottman","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib47","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-01-0248","article-title":"CCR5-binding chemokines modulate CXCL12 (SDF-1)\u2013induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor","volume":"100","author":"Honczarenko","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.09.001_bib48","article-title":"Targeted Gene Delivery: Where to Land","volume":"2","author":"Pavani","year":"2020","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.ymthe.2025.09.001_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.09.001_bib50","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.omtm.2021.11.007","article-title":"Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases","volume":"24","author":"Rintz","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.09.001_bib53","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1038\/s41467-022-31344-x","article-title":"Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency","volume":"13","author":"De Ravin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.001_bib54","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMe2409399","article-title":"Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"391","author":"Dunbar","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.001_bib55","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2024025828","article-title":"T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.09.001_bib56","first-page":"442","article-title":"Adeno-associated virus vector integration","volume":"11","author":"Deyle","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib57","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1089\/hum.2017.009","article-title":"Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models","volume":"28","author":"Chandler","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.09.001_bib58","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.09.001_bib59","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114188","article-title":"Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T-cells for the treatment of Hyper IgM1","volume":"42","author":"Canarutto","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2025.09.001_bib60","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.001_bib61","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41587-024-02171-w","article-title":"Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors","volume":"43","author":"Suchy","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.001_bib62","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1038\/s41467-022-33787-8","article-title":"Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo","volume":"13","author":"Cheng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.001_bib63","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3324\/haematol.2008.003020","article-title":"F9 Malm\u00f6, factor IX and deep vein thrombosis","volume":"94","author":"Bezemer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.09.001_bib64","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1182\/blood-2011-03-340711","article-title":"Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome","volume":"119","author":"Astrakhan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.09.001_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR Edits from Sanger Trace Data","volume":"5","author":"Conant","year":"2022","journal-title":"CRISPR J."},{"key":"10.1016\/j.ymthe.2025.09.001_bib66","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.omtm.2021.03.024","article-title":"CRISPAltRations: a validated cloud-based approach for interrogation of double-strand break repair mediated by CRISPR genome editing","volume":"21","author":"Kurgan","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.09.001_bib68","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fimmu.2018.00152","article-title":"Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice","volume":"9","author":"Hanazawa","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:34:13Z","timestamp":1783020853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625007294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1525001625007294"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.001","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.06.647090","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}